Asset Publisher

mp-270

print Print Back Back

Low-Level Laser Therapy

Policy Number: MP-270

Latest Review Date: June 2024

Category: Therapy                            

Note: Coverage may be subject to legislative mandates, including but not limited to the following, which apply prior to the policy statements:

In accordance with the mandate listed above, Low-level laser therapy is covered when used to treat lymphedema resulting from a mastectomy and ordered by the individual’s treating physician.

POLICY:

Low-level laser therapy may be considered medically necessary for prevention of oral mucositis in individuals undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic cell transplantation.

Low-level laser therapy is considered investigational for ALL other indications including but not limited to:

  • Adhesive capsulitis;
  • Arthritis conditions;
  • Bell palsy;
  • Carpal tunnel syndrome;
  • Fibromyalgia;
  • Headache;
  • Heel pain (i.e., Achilles tendinopathy, plantar fasciitis);
  • Knee pain;
  • Lateral epicondylitis (tennis elbow);
  • Low back pain;
  • Lymphedema (not related to post-mastectomy lymphedema);
  • Musculoskeletal disorders;
  • Myofascial Pain ;
  • Neck pain;
  • Neurological dysfunctions;
  • Osteoarthritic knee pain;
  • Plantar fasciitis;
  • Raynaud’s phenomenon;
  • Rheumatoid arthritis;
  • Shoulder pain;
  • Smoking cessation;
  • Subacromial impingement;
  • Temporomandibular joint dysfunction;
  • Trismus;
  • Weight loss/Appetite suppression;
  • Wound healing.

DESCRIPTION OF PROCEDURE OR SERVICE:

Low-level laser therapy (LLLT), also called photobiomodulation, is being evaluated to treat various conditions, including, among others, oral mucositis, myofascial pain, joint pain, lymphedema, and chronic wounds.

Oral Mucositis

Oral mucositis describes inflammation of the oral mucosa and typically manifests as erythema or ulcerations that appear seven to ten days after initiation of high-dose cancer therapy. Oral mucositis can cause significant pain and increased risk of systemic infection, dependency on total parenteral nutrition, and use of opioid analgesics.

Treatment

Treatment planning may also need to be modified due to dose-limiting toxicity. There are a number of interventions for oral mucositis that may partially control symptoms, but none is considered a criterion standard treatment. When uncomplicated by infection, oral mucositis is self-limited and usually heals within two to four weeks after cessation of cytotoxic chemotherapy. Low-level laser therapy (LLLT) has been used in cancer therapy-induced oral mucositis in individuals treated with radiotherapy and/or chemotherapy and hematopoietic cell transplantation.

Musculoskeletal and Neurologic Disorders

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and the most commonly performed surgery of the hand. The syndrome is related to the bony anatomy of the wrist. The carpal tunnel is bound dorsally and laterally by the carpal bones and ventrally by the transverse carpal ligament. Through this contained space run the nine flexor tendons and the median nerve. Therefore, any space-occupying lesion can compress the median nerve and produce the typical symptoms of CTS-pain, numbness, and tingling in the distribution of the median nerve. Symptoms of more severe cases include hypesthesia, clumsiness, loss of dexterity, and weakness of pinch. In the most severe cases, individuals experience marked sensory loss and significant functional impairment with thenar atrophy.

Treatment

Several modalities of treatment are used in the management of musculoskeletal pain including medications, immobilization, and physical therapy. The use of LLLT has been investigated for use in musculoskeletal pain conditions. In the case of CTS, mild-to-moderate cases are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs, and steroid injections into the carpal tunnel itself.

Individuals who do not respond to conservative therapy or who present with severe CTS with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach. Low-level laser therapy is also used to treat CTS.

Wound Care and Lymphedema

Chronic wounds are wounds that do not improve after 4 weeks or heal within 8 weeks. These include diabetic foot ulcers, venous-related ulcerations, non-healing surgical wounds, and pressure ulcers. They are often found on the feet, ankles, heels, calves, and on the hips, thighs, and buttocks of those who cannot walk.

Lymphedema is described as swelling in at least 1 leg and/or arm. It is commonly caused by the removal of a lymph node. The resulting blockage of the lymphatic system prevents lymph fluid from draining well, leading to fluid build-up and swelling. Other symptoms can include heaviness or tightness in the affected limb, restricted range of motion, aching or discomfort, recurring infections, and dermal fibrosis. Risk factors for developing lymphedema after cancer from cancer treatment or from other secondary causes can include older age, obesity, and rheumatoid or psoriatic arthritis.

Treatment

Several modalities of treatment are used in the management of musculoskeletal pain including medications, immobilization, and physical therapy. The use of LLLT has been investigated for use in musculoskeletal pain conditions. In the case of CTS, mild-to-moderate cases are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs, and steroid injections into the carpal tunnel itself.

Individuals who do not respond to conservative therapy or who present with severe CTS with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach. Low-level laser therapy is also used to treat CTS.

Low-Level Laser Therapy

LLLT is the use of red-beam or near-infrared lasers with a wavelength between 600 and 1000 nm and power between 5 and 500 MW. (By comparison, lasers used in surgery typically use 300 W.) When applied to the skin, LLLT produces no sensation and does not burn the skin. Because of the low absorption by human skin, it is hypothesized that the laser light can penetrate deeply into the tissues where it has a photobiostimulative effect. The exact mechanism of its effect on tissue healing is unknown; hypotheses have included improved cellular repair and stimulation of the immune, lymphatic, and vascular systems.

LLLT is being evaluated to treat a wide variety of conditions, including soft tissue injuries, myofascial pain, tendinopathies, nerve injuries, joint pain, and lymphedema.

KEY POINTS:

This evidence review was created and updated regularly with a search of the PubMed database. The most recent literature update was performed through April 18, 2024.

Summary of Evidence:

Oral Mucositis

For individuals who have an increased risk of oral mucositis due to some cancer treatments (e.g., chemotherapy, radiotherapy)and/or hematopoietic cell transplantation (HCT) who receive low-level laser therapy (LLLT), the evidence includes systematic reviews and 1 RCT in leukemic children . Relevant outcomes are symptoms, morbid events, quality of life (QOL), and treatment-related morbidity. Several systematic reviews of RCTs have found better outcomes with LLLT used to prevent oral mucositis than with control treatments. Results have consistently supported a reduction in severe oral mucositis in patients undergoing chemotherapy, HCT, radiotherapy, and chemoradiotherapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Musculoskeletal and Neurologic Disorders

For individuals who have carpal tunnel syndrome (CTS) who receive LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Both a 2016 systematic review and a 2010 TEC Assessment did not find sufficient evidence from RCTs that LLLT improves outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have neck pain who receive LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. A 2013 systematic review identified 17 trials, most of which were considered low quality. Only two trials were considered moderate quality and they found that LLLT led to better outcomes than placebo for chronic neck pain. A 2010 TEC Assessment found conflicting evidence. Additionally, laser types, application dosages, and treatment schedules vary in the available evidence and require further study. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have subacromial impingement syndrome who receive LLLT, the evidence includes RCTs. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Most trials did not show a significant benefit of LLLT compared with sham treatment or with an alternative intervention (e.g., exercise). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have adhesive capsulitis who receive LLLT, the evidence includes RCTs and a systematic review. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. A Cochrane review on treatments for adhesive capsulitis identified two RCTs assessing LLLT. Due to the small number of trials and study limitations, reviewers concluded that the evidence was insufficient to permit conclusions about the effectiveness of LLLT for adhesive capsulitis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have temporomandibular joint (TMJ) pain who receive LLLT, the evidence includes RCTs and several systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Meta-analyses of RCTs had mixed findings. A 2021 meta-analysis, which included 33 placebo-controlled RCTs, found a statistically significant impact of LLLT on pain scores and improved functional outcomes (e.g., mouth opening). Furthermore, RCTs have not compared the impact of LLLT with physical therapy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have low back pain who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Meta-analyses of RCTs found that LLLT resulted in a significantly greater reduction in pain scores and global assessment scores than a placebo control in the immediate posttreatment setting. Meta-analyses have found conflicting evidence regarding other outcomes (e.g., disability index, range of motion). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have osteoarthritis (OA) knee pain who receive low LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. A 2020 systematic review, which pooled study findings, did find that LLLT significantly improved pain or functional outcomes compared with a sham intervention; however, the study was limited by high heterogeneity and inconsistency between regimens and follow-up duration. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have heel pain (i.e., Achilles tendinopathy, plantar fasciitis) who receive LLLT, the evidence includes RCTs. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Findings of sham-controlled randomized trials were inconsistent, and RCTs lack long-term follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have rheumatoid arthritis (RA) who receive low LLLT, the evidence includes RCTs and a systematic review. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A systematic review of RCTs found an inconsistent benefit of LLLT for a range of outcomes. A 2010 RCT, published after the systematic review, did not find that LLLT was significantly better than a placebo treatment on most outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have Bell palsy who receive LLLT, the evidence includes 2 RCTs and 1 nonrandomized controlled trial. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. One RCT found a significant short-term benefit of LLLT over exercise. Longer-term outcomes beyond 6 weeks were not available. Because Bell's palsy often improves within weeks and may completely resolve within months, it is difficult to isolate specific improvements from laser therapy over the natural resolution of the illness. In addition, no sham-controlled trials are available. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have fibromyalgia who receive LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The RCTs evaluating LLLT for the treatment of fibromyalgia are small. One RCT (n=20 patients) found significantly better outcomes with LLLT than with sham, while another (n=20 patients) did not find statistically significant between-group differences for similar outcomes. A larger (N=42) study found improved pain and QOL with LLLT; however, the trial was conducted at a single center with strict inclusion criteria. Additional RCTs with sufficient numbers of patients are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Wound Care and Lymphedema

For individuals who have chronic non-healing wounds who receive LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The few existing RCTs tend to have small sample sizes and potential risk of bias. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have lymphedema who receive LLLT, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Multiple systematic reviews found methodologic flaws in the available studies and did not consistently find better outcomes for patients receiving LLLT than receiving a control condition for the treatment of lymphedema. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements:

American Academy of Orthopaedic Surgeons

In 2016, the American Academy of Orthopaedic Surgeons' guidelines on the management of carpal tunnel syndrome indicated the: "limited evidence supports that laser therapy might be effective compared to placebo."

American College of Physicians

In 2017, the American College of Physicians (ACP) released guidelines relating to noninvasive treatments for chronic low back pain. The guidelines strongly recommended that patients with chronic low back pain should first seek non-pharmacologic treatment such as exercise, multidisciplinary rehabilitation, acupuncture, and mindfulness-based stress reduction-all based on moderate quality evidence. The recommendation also stated that patients with chronic low back pain should seek treatments such as tai chi, yoga, motor control exercise, progressive relaxation, electromyography biofeedback, LLLT, operant therapy, cognitive behavioral therapy, or spinal manipulation-all based on low-quality evidence. While the ACP stated that LLLT has a small effect on pain and function, it found the evidence insufficient for the use of LLLT.

In 2020, the American College of Physicians published a joint guideline on the management of acute pain from non-low back musculoskeletal injuries with the American Academy of Family Physicians. No recommendations are made specific to LLLT, but the guideline notes that laser therapy did not significantly reduce pain in 1 to 7 days compared to placebo.

American Physical Therapy Association

In 2018, the American Physical Therapy Association published an updated guideline on the diagnosis and treatment of Achilles tendinitis. The use of LLLT was given a level D recommendation, meaning that no recommendation could be made due to contradictory evidence. This is a change from the previous version of the guideline published in 2010, which gave LLLT a level B recommendation.

Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology

In 2017, the Mucositis Prevention Guideline Development Group published guidelines on preventing oral and oropharyngeal mucositis in children undergoing hematopoietic cell transplantation. The guidelines were based on an evidence review consisting of randomized controlled trials that evaluated interventions such as cryotherapy and low-level laser therapy (LLLT). The guidelines suggested that LLLT could be offered to children but classified this recommendation as weak.

In 2020, the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology published joint guidelines on the management of mucositis secondary to cancer therapy.

For the prevention of oral mucositis, the 2 associations recommended the following treatments, based on level 1 evidence: LLLT in patients undergoing radiotherapy with chemotherapy for head and neck cancer; LLLT in patients receiving hematopoietic cell transplantation conditioned with high-dose chemotherapy with or without total body irradiation; recombinant human keratinocyte growth factor-1 in patients receiving high-dose chemotherapy and total body irradiation, followed by autologous cell transplantation for hematologic malignancy; and benzydamine mouthwash in patients with head and neck cancer receiving moderate-dose radiotherapy without concomitant chemotherapy.

Additionally, numerous treatments were recommended for the prevention of oral mucositis based on level II evidence, including LLLT in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer. Several LLLT protocols are outlined by the guideline based on cancer treatment modality, ranging in wavelength from 632.9 to 660 nm.

National Institute for Health and Clinical Excellence

In 2009, NICE issued guidance on early management of persistent nonspecific low back pain did not recommend laser treatment, citing limited evidence. The 2016 and 2020 updated guidance does not mention laser therapy.

North American Spine Society

In 2020, the North American Spine Society published a guideline on the diagnosis and treatment of low back pain. The guideline was based on a systematic review of the literature to address key clinical questions regarding the diagnosis and treatment of adults with nonspecific low back pain.

Table 1. North American Spine Society Guideline Recommendations for Laser Therapy

Guideline Recommendation

Grade of Recommendation

"It is suggested that the combination of laser therapy (low-level or high-level) with exercise provides better short-term relief of pain than either exercise or laser therapy alone."

B

"There is conflicting evidence that the combination of laser therapy with exercise provides better short-term improvement in function compared to exercise or laser therapy alone."

I

"It is suggested that there is no short-term benefit of laser therapy (low-level or high-level) when compared with exercise alone."

B

Grade of Recommendation (levels of evidence range from Level I [high quality randomized controlled trial] to Level V [expert consensus]): A=Good evidence (Level I studies with consistent findings) for or against recommending intervention; B=Fair evidence (Level II or III studies with consistent findings) for or against recommending intervention; C=Poor quality evidence (Level IV or V studies) for or against recommending intervention; I=Insufficient or conflicting evidence not allowing a recommendation for or against intervention

U.S. Preventive Services Task Force Recommendations:

Not applicable.

KEY WORDS:

Low-level laser therapy (LLLT), laser therapy, cold laser, cold laser therapy, class III laser, Micro Light laser,  photobiomodulation, high power laser therapy (HPLT), class IV high power laser, MLS laser therapy, Cutting Edge MLS M6 Robotic Laser, Avicenna’s laser, GRT LITE, Excalibur IV Laser, Acculaser Pro, Tuco Erchonia PL3000, Light Stream low-level laser, FX-635, Super Pulsed Laser Technology, WHCRA, Women's Health and Cancer Rights Act 

APPROVED BY GOVERNING BODIES:

Table 2. Low-Level Laser Therapy Devices Cleared by the U.S. Food and Drug Administration

Device

Manufacturer

Date Cleared

510 (k)

Indication

FX-635

Erchonia Corporation

6/01/2019

K190572

For adjunctive use in whole body musculoskeletal pain therapy

Super Pulsed Laser

Technology

Multi Radiance Medical

01/13/2018

K171354

Providing temporary relief of minor chronic neck and

shoulder pain of musculoskeletal origin

Lightstream Low-Level

Laser

SOLICA

CORPORATION

04/03/2009

K081166

For adjunctive use in the temporary relief of pain

associated with knee disorders with standard

chiropractic practice

GRT LITE, MODEL 8-A

GRT SOLUTIONS, INC.

02/03/2006

K050668

Use in providing temporary relief of minor chronic

neck and shoulder pain of musculoskeletal origin

MICROLIGHT 830 LASER

SYSTEM

MICROLIGHT

CORPORATION OF

AMERICA

02/06/2002

K010175

Use in pain therapy or related indication

 

A number of low-level lasers have been cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for the treatment of pain. Data submitted for the MicroLight 830® Laser consisted of the application of the laser over the carpal tunnel 3 times a week for 5 weeks. The labeling states that the "MicroLight 830 Laser is indicated for adjunctive use in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome." In 2006, GRT LITE™ was cleared for marketing, listing the TUCO Erchonia PL3000, the Excalibur System, the MicroLight 830® Laser, and the Acculaser Pro as predicate devices. Indications of the GRT LITE™ for CTS are similar to the predicate devices: "adjunctive use in providing temporary relief of minor chronic pain." In 2009, the LightStream™ LLL device was cleared for marketing by the FDA through the 510(k) process for adjunctive use in the temporary relief of pain associated with knee disorders treated in standard chiropractic practice. A number of clinical trials of LLLT are underway in the U.S., including studies of wound healing. Since 2009, many more similar LLLT devices have received 510(k) clearance from the FDA.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits.  Group-specific policy will supersede this policy when applicable.

ITS: Home Policy provisions apply

FEP contracts: Special benefit consideration may apply. Refer to member’s benefit plan.

CURRENT CODING:

CPT Codes

97026   Application of a modality to one or more area; infrared
97037 Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non ablative) for post-operative pain reduction (Effective 1/1/24)
97039   Unlisted modality (specify type and time if constant attendance)
97139   Unlisted therapeutic procedure
0552T  Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional (Effective 07/01/19)

                                                                  

HCPCS  Codes

S8948 Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes

                                       

REFERENCES:

  1. Abrisham SM, Kermani-Alghoraishi M, Ghahramani R et al. Additive effects of low-level laser therapy with exercise on subacromial syndrome: a randomized, double-blind, controlled trial. Clin Rheumatol 2011; 30(10):1341-6.
  2. Aisaiti A, Zhou Y, Wen Y, et al. Effect of photobiomodulation therapy on painful temporomandibular disorders. Sci Rep. Apr 27 2021; 11(1): 9049.
  3. Alayat MS, Elsoday AM, El Fiky AA. Efficacy of high and low level laser therapy in the treatment of Bell’s palsy: A randomized double blind placebo-controlled trial. Lasers Med Sci 2013.
  4. Alfredo PP, Bjordal JM, Dreyer SH et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. Clin Rehabil 2012; 26(6):523- 33.
  5. Alfredo PP, Bjordal JM, Junior WS, et al. Efficacy of low-level laser therapy combined with exercise for subacromial impingement syndrome: A randomised controlled trial. Clin Rehabil. Dec 14 2020: 269215520980984.
  6. Alfredo PP, Bjordal JM, Junior WS, et al. Efficacy of low-level laser therapy combined with exercise for subacromial impingement syndrome: A randomised controlled trial. Clin Rehabil. Jun 2021; 35(6): 851-860.
  7. American Academy of Orthopaedic Surgeons. Management of Carpal Tunnel Syndrome: Evidence-Based Clinical Guideline. 2016; www.aaos.org/uploadedFiles/PreProduction/Quality/Guidelines_and_Reviews/guidelines/CTS%20CPG_6%207%202016.pdf.
  8. Antunes HS, Herchenhorn D, Small IA et al. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 2013. 
  9. Arribas-Pascual M, Hernández-Hernández S, Jiménez-Arranz C, et al. Effects of Physiotherapy on Pain and Mouth Opening in Temporomandibular Disorders: An Umbrella and Mapping Systematic Review with Meta-Meta-Analysis. J Clin Med. Jan 18 2023; 12(3).
  10. Ay S, Dogan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low back pain? Clin Rheumatol 2010; 29(8):905-10.
  11. Badil Guloglu S. Comparison of low-level laser treatment and extracorporeal shock wave therapy in subacromial impingement syndrome: a randomized, prospective clinical study. Lasers Med Sci. Jun 2021; 36(4): 773-781.
  12. Barbosa RI, Fonseca MC, Rodrigues EK, et al. Efficacy of low-level laser therapy associated to orthoses for patients with carpal tunnel syndrome: A randomized single-blinded controlled trial. J Back Musculoskelet Rehabil. Sep 25 2015.
  13. Blue Cross and Blue Sheld Technology Evaluation Center (TEC). Low-level laser therapy for carpal tunnel syndrome and chronic neck pain. TEC Assessment. Nov 2010; Vol 25, Tab 4.
  14. Calis HT, Berberoglu N, Calis M. Are ultrasound, laser and exercise superior to each other in the treatment of subacromial impingement syndrome? A randomized clinical trial. Eur J Phys Rehabil Med 2011.
  15. Carcia CR, Martin RL, Houck J et al. Achilles pain, stiffness, and muscle power deficits: achilles tendinitis. J Orthop Sports Phys Ther 2010; 40(9):A1-26.
  16. Chamani G, Zarei MR, Rad M, et al. Comparison of low-level laser therapy and standard treatment for temporomandibular disorders: An assessment of therapeutic and placebo effects. J Oral Rehabil. Apr 2024; 51(4): 657-665. 
  17. Chang WD, Lee CL, Lin HY, et al. A Meta-analysis of Clinical Effects of Low-level Laser Therapy on Temporomandibular Joint Pain. J Phys Ther Sci. Aug 2014; 26(8):1297-1300.
  18. Chen C, Hou WH, Chan ES, et al. Phototherapy for treating pressure ulcers. Cochrane Database Syst Rev. 2014; 7:CD009224.
  19. Chen J, Huang Z, Ge M, et al. Efficacy of low-level laser therapy in the treatment of TMDs: a meta-analysis of 14 randomized controlled trials. J Oral Rehabil. Apr 2015; 42(4):291-299.
  20. Chen YJ, Liao CD, Hong JP, et al. Effects of laser therapy on chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. Clin Rehabil. Mar 2022; 36(3): 289-302.
  21. Chiu ST, Lai UH, Huang YC, et al. Effect of various photobiomodulation regimens on breast cancer-related lymphedema: A systematic review and meta-analysis. Lasers Med Sci. Dec 22 2023; 39(1): 11.
  22. Cinar E, Saxena S, Uygur F. Low-level laser therapy in the management of plantar fasciitis: a randomized controlled trial. Lasers Med Sci. Jul 2018;33(5):949-958.
  23. Cruz AR, Minicucci EM, Betini M, et al. Efficacy of photobiomodulation in the treatment of oral mucositis in patients undergoing antineoplastic therapy: systematic review and meta-analysis. Support Care Cancer. Oct 19 2023; 31(12): 645.
  24. Del Vecchio A, Floravanti M, Boccassini A, et al. Evaluation of the efficacy of a new low-level laser therapy home protocol in the treatment of temporomandibular joint disorder-related pain: A randomized, double-blind, placebo controlled clinical trial. Cranio. Mar 2021; 39(2): 141-150.
  25. Desai AP, Roy SK, Semi RS, et al. Efficacy of Low-Level Laser Therapy in Management of Temporomandibular Joint Pain: A Double Blind and Placebo Controlled Trial. J Maxillofac Oral Surg. Sep 2022; 21(3): 948-956.
  26. Doeuk C, Hersant B, Bosc R, et al. Current indications for low level laser treatment in maxillofacial surgery: a review. Br J Oral Maxillofac Surg. Apr 2015; 53(4):309-315.
  27. Dogan SK, Ay S, Evcik D. The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. Clinics (Sao Paulo) 2010; 65(10):1019-22.
  28. Ekici Ö, Dündar Ü, Büyükbosna M. Comparison of the Efficiency of High-Intensity Laser Therapy and Transcutaneous Electrical Nerve Stimulation Therapy in Patients With Symptomatic Temporomandibular Joint Disc Displacement With Reduction. J Oral Maxillofac Surg. Jan 2022; 80(1): 70-80.
  29. Ekici Ö, Dündar Ü, Büyükbosna M. Effectiveness of high-intensity laser therapy in patients with myogenic temporomandibular joint disorder: A double-blind, placebo-controlled study. J Stomatol Oral Maxillofac Surg. Jun 2022; 123(3): e90-e96. 
  30. Ekici Ö, Dündar Ü, Gökay GD, et al. Evaluation of the efficiency of different treatment modalities in individuals with painful temporomandibular joint disc displacement with reduction: a randomised controlled clinical trial. Br J Oral Maxillofac Surg. Apr 2022; 60(3): 350-356.
  31. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy..Jul 28 2020.
  32. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. Oct 01 2020; 126(19): 4423-4431.
  33. Ferlito JV, Silva CF, Almeida JC, et al. Effects of photobiomodulation therapy (PBMT) on the management of pain intensity and disability in plantar fasciitis: systematic review and meta-analysis. Lasers Med Sci. Jul 18 2023; 38(1): 163.
  34. Ferreira B, da Motta Silveira FM, de Orange FA. Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support Care Cancer. Mar 2016; 24(3):1035-1042.
  35. Figueiredo AL, Lins L, Cattony AC et al. Laser therapy in the control of oral mucositis:  a meta-analysis. Rev Assoc Med Bras 2013.
  36. Fornaini C, Pelosi A, Queirolo V, et al. The "at-home LLLT" in temporo-mandibular disorders pain control: a pilot study. Laser Ther. Mar 31 2015; 24(1): 47-52.
  37. Franco R, Lupi E, Iacomino E, et al. Low-Level Laser Therapy for the Treatment of Oral Mucositis Induced by Hematopoietic Stem Cell Transplantation: A Systematic Review with Meta-Analysis. Medicina (Kaunas). Aug 03 2023; 59(8). 
  38. Fulop AM, Dhimmer S, Deluca JR et al. A meta-analysis of the efficacy of laser phototherapy on pain relief. Clin J Pain 2010; 26(8):729-36.
  39. Fusakul Y, Aranyavalai T, Saensri P, et al. Low-level laser therapy with a wrist splint to treat carpal tunnel syndrome: a double-blinded randomized controlled trial. Lasers Med Sci. May 2014;29(3):1279-1287.
  40. Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low Level Helium Neon Laser therapy for chemoradiotherapy induced oral mucositis in oral cancer patients - A randomized controlled trial. Oral Oncol 2012; 48(9):893-7.
  41. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low level laser therapy against radiation induced oral mucositis in elderly head and neck cancer patients-a randomized placebo controlled trial. J Photochem Photobiol B. Mar 2015; 144:51-56.
  42. Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - A triple blinded randomized controlled trial. Radiother Oncol 2012; 104(3):349-54.
  43. Gautam AP, Fernandes DJ, Vidyasagar MS et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy—a randomized controlled trial. Support Care Cancer 2013; 21(5):1421-8.
  44. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low back pain: a meta-analysis of randomized controlled trials. Acupunct Med. Oct 2016; 34(5):328-341.
  45. Gross AR, Dziengo S, Boers O et al. Low level laser therapy (LLLT) for neck pain: a systematic review and meta-regression. Open Orthop J 2013; 7:396-419.
  46. Guimaraes JS, Arcanjo FL, Leporace G, et al. Effect of low-level laser therapy on pain and disability in patients with plantar fasciitis: A systematic review and meta-analysis. Musculoskelet Sci Pract. Feb 2022; 57: 102478.
  47. Hanna R, Dalvi S, Bensadoun RJ, et al. Role of Photobiomodulation Therapy in Modulating Oxidative Stress in Temporomandibular Disorders. A Systematic Review and Meta-Analysis of Human Randomised Controlled Trials. Antioxidants (Basel). Jun 25 2021; 10(7).
  48. Honda Y, Sakamoto J, Hamaue Y, et al. Effects of Physical-Agent Pain Relief Modalities for Fibromyalgia Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Res Manag. 2018 Oct 1;2018:2930632.
  49. Huang Z, Chen J, Ma J, et al. Effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. Sep 2015; 23(9):1437-1444.
  50. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
  51. Jang H, Lee H. Meta-analysis of pain relief effects by laser irradiation on joint areas. Photomed Laser Surg 2012; 30(8):405-17.
  52. Kiritsi O, Tsitas K, Malliaropoulos N et al. Ultrasonographic evaluation of plantar fasciitis after low-level laser therapy: results of a double-blind, randomized, placebo-controlled trial. Lasers Med Sci 2010; 25(2):275-81.
  53. Konstantinovic LM, Cutovic MR, Milovanovic AN et al. Low-level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med 2010; 11(8):1169-78.
  54. Koldas Dogan S, Ay S, Evcik D. The effects of two different low level laser therapies in the treatment of patients with chronic low back pain: A double-blinded randomized clinical trial. J Back Musculoskelet Rehabil. Jul 2017;30(2):235-240.
  55. Konstantinovic LM, Kanjuh ZM, Milovanovic AN et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28(4):553-60.
  56. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. May 15 2014; 120(10):1453-1461.
  57. Li ZJ, Wang Y, Zhang HF, et al. Effectiveness of low-level laser on carpal tunnel syndrome: A meta-analysis of previously reported randomized trials. Medicine (Baltimore). Aug 2016; 95(31):e4424.
  58. Lin W, Zhou F, Yu L, et al. Quantitative sensory testing of periauricular skin in healthy adults. Sci Rep. Feb 28 2020; 10(1): 3728.
  59. Lourinho I, Sousa T, Jardim R, et al. Effects of low-level laser therapy in adults with rheumatoid arthritis: A systematic review and meta-analysis of controlled trials. PLoS One. 2023; 18(9): e0291345.
  60. Machado RS, Viana S, Sbruzzi G. Low-level laser therapy in the treatment of pressure ulcers: systematic review. Lasers Med Sci. May 2017;32(4):937-944.
  61. Macias DM, Coughlin MJ, Zang K, et al. Low-level laser therapy at 635 nm for treatment of chronic plantar fasciitis: a placebo-controlled, randomized study. J Foot Ankle Surg. Sep-Oct 2015; 54(5):768-772.
  62. Madani A, Ahrari F, Fallahrastegar A, et al. A randomized clinical trial comparing the efficacy of low-level laser therapy (LLLT) and laser acupuncture therapy (LAT) in patients with temporomandibular disorders. Lasers Med Sci. Feb 2020; 35(1): 181-192.
  63. Malliaropoulos N, Kiritsi O, Tsitas K et al.  Low-level laser therapy in meniscal pathology: a double-blinded placebo-controlled trial.  Lasers Med Sci 2013; 28(4):1183-8. 
  64. Magri LV, Bataglion C, Leite-Panissi CRA. Follow-up results of a randomized clinical trial for low-level laser therapy in painful TMD of muscular origins. Cranio. Nov 2021; 39(6): 502-509.
  65. Marini I, Gatto MR, Bonetti GA. Effects of superpulsed low-level laser therapy on temporomandibular joint pain. Clin J Pain 2010; 26(7):611-6.
  66. Martin RL, Chimenti R, Cuddeford T, et al. Achilles Pain, Stiffness, and Muscle Power Deficits: Midportion Achilles Tendinopathy Revision 2018.. May 2018; 48(5): A1-A38.
  67. Meireles SM, Jones A, Jennings F et al. Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: a randomized double-blind controlled trial. Clin Rheumatol 2010; 29(5):501-9.
  68. Migliorati C, Hewson I, Lalla RV et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 2012.
  69. Naterstad IF, Joensen J, Bjordal JM, et al. Efficacy of low-level laser therapy in patients with lower extremity tendinopathy or plantar fasciitis: systematic review and meta-analysis of randomised controlled trials. BMJ Open. Sep 28 2022; 12(9): e059479.
  70. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management [NG59]. 2016; www.nice.org.uk/guidance/NG59/chapter/Recommendations.
  71. Navarro-Ledesma S, Carroll J, Burton P, et al. Short-Term Effects of Whole-Body Photobiomodulation on Pain, Quality of Life and Psychological Factors in a Population Suffering from Fibromyalgia: A Triple-Blinded Randomised Clinical Trial. Pain Ther. Feb 2023;12(1): 225-239.
  72. Navarro-Ledesma S, Carroll J, González-Muñoz A, et al. Changes in Circadian Variations in Blood Pressure, Pain Pressure Threshold and the Elasticity of Tissue after a Whole-Body Photobiomodulation Treatment in Patients with Fibromyalgia: A Tripled-Blinded Randomized Clinical Trial. Biomedicines. Oct 23 2022; 10(11).
  73. News Now Staff. Laser Therapy a Slight Winner in Analysis of Electrotherapy Modalities for Adhesive Capsulitis PT in Motion News 2014; http://www.apta.org/PTinMotion/News/2014/10/3/LaserTherapyCapsulitis/.
  74. North American Spine Society. Evidence-based clinical guidelines for multidisciplinary spine care. 2020. https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf.
  75. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One. 2014; 9(9):e107418.
  76. Omar MT, Shaheen AA, Zafar H. A systematic review of the effect of low-level laser therapy in the management of breast cancer-related lymphedema. Support Care Cancer 2012; 20:2977-84.
  77. Omar MTA, Ebid AA, El Morsy AM. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study. J Surg Res 2011; 165(1):82-90.
  78. Ordahan B, Karahan AY. Role of low-level laser therapy added to facial expression exercises in patients with idiopathic facial (Bell's) palsy. Lasers Med Sci. May 2017;32(4):931-936.
  79. Oton-Leite AF, Correa de Castro AC, Morais MO et al. Effect of intraoral low-level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy. Head Neck 2012; 34(3):398-404.
  80. Oton-Leite AF, Silva GB, Morais MO, et al. Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients. Lasers Surg Med. Apr 2015; 47(4):296-305.
  81. Page MJ, Green S, Kramer S, et al. Electrotherapy modalities for adhesive capsulitis (frozen shoulder). Cochrane Database Syst Rev. Oct 1 2014; 10:CD011324.
  82. Peng J, Shi Y, Wang J, et al. Low-level laser therapy in the prevention and treatment of oral mucositis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. Oct 2020; 130(4): 387-397.e9.
  83. Petrucci A, Sgolastra F, Gatto R et al. Effectiveness of low-level laser therapy in temporomandibular disorders: a systematic review and meta-analysis. J Orofac Pain 2011; 25(4):298-307.
  84. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Apr 4 2017; 166(7):514-530.
  85. Qaseem A, McLean RM, O'Gurek D, et al. Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians.. Aug 18 2020.
  86. Qaseem A, McLean RM, O'Gurek D, et al. Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians. Ann Intern Med. Nov 03 2020; 173(9): 739-748.
  87. Rankin IA, Sargeant H, Rehman H, et al. Low-level laser therapy for carpal tunnel syndrome.Cochrane. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012765/full Published 22 August 2017.
  88. Rayegani S, Bahrami M, Samadi B et al. Comparison of the effects of low energy laser and ultrasound in treatment of shoulder myofascial pain syndrome: a randomized single-blinded clinical trial. Eur J Phys Rehabil Med 2011; 47(3):381-9.
  89. Reyad FA, Elsayed NM, El Chazli Y. Photobiomodulation for chemotherapy-induced oral mucositis in leukemic children: A randomized controlled clinical trial. Oral Dis. Jul 2023; 29(5): 2239-2247.
  90. Ruaro JA, Frez AR, Ruaro MB, et al. Low-level laser therapy to treat fibromyalgia. Lasers Med Sci. Nov 2014; 29(6):1815-1819.
  91. Santos Tde S, Piva MR, Ribeiro MH, et al. Laser therapy efficacy in temporomandibular disorders: control study. Braz J Otorhinolaryngol. 2010; 76(3): 294-9.
  92. Shen B, Zhou Y, Wu D, et al. Efficacy of photobiomodulation therapy in the management of oral mucositis in patients with head and neck cancer: A systematic review and meta-analysis of randomized controlled trials. Head Neck. Apr 2024; 46(4): 936-950. 
  93. Shobha R, Narayanan VS, Jagadish Pai BS, et al. Low-level laser therapy: A novel therapeutic approach to temporomandibular disorder - A randomized, double-blinded, placebo-controlled trial. Indian J Dent Res. Jul-Aug 2017;28(4):380-387.
  94. Shousha T, Alayat M, Moustafa I. Effects of low-level laser therapy versus soft occlusive splints on mouth opening and surface electromyography in females with temporomandibular dysfunction: A randomized-controlled study. PLoS One. 2021; 16(10): e0258063.
  95. Smoot B, Chiavola-Larson L, Lee J, et al. Effect of low-level laser therapy on pain and swelling in women with breast cancer-related lymphedema: a systematic review and meta-analysis. J Cancer Surviv. Jun 2015; 9(2):287- 304.
  96. Stausholm MB, Naterstad IF, Joensen J, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials.. Oct 28 2019; 9(10): e031142.
  97. Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care. Mar 2017;7(1):7-16.
  98. Taradaj J, Halski T, Kucharzewski M, et al. Effect of laser irradiation at different wavelengths (940, 808, and 658 nm) on pressure ulcer healing: results from a clinical study. Evid Based Complement Alternat Med 2013;2013:960240.
  99. Tascioglu F, Degirmenci NA, Ozkan S et al. Low-level laser in the treatment of carpal tunnel syndrome: clinical, electrophysiological, and ultrasonographical evaluation. Rheumatol Int 2010.
  100. Tumilty S, McDonough S, Hurley DA et al. Clinical effectiveness of low-level laser therapy as an adjunct to eccentric exercise for the treatment of Achilles' tendinopathy: a randomized controlled trial. Arch Phys Med Rehabil 2012; 93(5):733-9.
  101. Tumilty S, Munn J, McDonough S, et al. Low level laser treatment of tendinopathy: A septematic review with meta-analysis. PhotoMedicine and Laser Surgery 2010; 28(1): 3-16.
  102. Venezian GC, da Silva MA, Mazzetto RG et al. Low level laser effects on pain to palpation and electromyographic activity in TMD patients: a double-blind, randomized, placebo-controlled study. Cranio 2010; 28(2):84-91.
  103. Wang W, Jiang W, Tang C, et al. Clinical efficacy of low-level laser therapy in plantar fasciitis: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Jan;98(3):e14088. 
  104. Wang X, Yang Z, Zhang W, et al. [Efficacy evaluation of low-level laser therapy on temporomandibular disorder]. Hua Xi Kou Qiang Yi Xue Za Zhi. Aug 2011; 29(4): 393-5, 399.
  105. Winters M, Esker M, Weir A et al. Treatment of medical tibial stress syndrome:  a systematic review. Sports Med 2013.
  106. World Association of Laser Therapy Recommended treatment doses for low level laser therapy. (revised April 2010). www.walt.nu/doseage-recommendations.html.
  107. Wu D, Zhao YL, Sun JY, et al. A Nonrandomized Trial of the Effects of Near-Infrared Photobiomodulation Therapy on Bell's Palsy with a Duration of Greater Than 8 Weeks. Photobiomodul Photomed Laser Surg. Sep 2023; 41(9): 490-500.
  108. Yamaner FE, Celakil T, Gökcen Roehlig B. Comparison of the efficiency of two alternative therapies for the management of temporomandibular disorders. Cranio. May 2022; 40(3): 189-198.
  109. Zhang Y, Qian Y, Huo K, et al. Efficacy of laser therapy for temporomandibular disorders: A systematic review and meta-analysis. Complement Ther Med. Jun 2023; 74: 102945.

 

POLICY HISTORY:

Medical Policy Group, May 2006 (3)

Medical Policy Administration Committee, June 2006

Available for comment July 5-August 18, 2006

Medical Policy Group, February 2007 (3)

Medical Policy Administration Committee, February 2007

Available for comment February 10-March 26, 2007

Medical Policy Group, March 2009 (4)

Medical Policy Administration Committee, April 2009

Available for comment March 18-May 1, 2009

Medical Policy Group, January 2010 (3)

Medical Policy Group, October 2010 (3)

Medical Policy Group, January 2010

Medical Policy Group, March 2011 (3)

Medical Policy Administration Committee March 2011

Available for comment April 4 – May 18, 2011

Medical Policy Group, December 2011 (3): Updated investigational list under Policy section, and updated Key Points, & References

Medical Policy Group, December 2012 (3): 2012 Updates to Description, Policy (added more indications), Key Points, and References

Medical Policy Administration Committee, January 2013

Available for comment December 12, 2012 through January 26, 2013

Medical Policy Panel, November 2013

Medical Policy Group, January 2014 (2): Policy statement unchanged.  Description, Key Points, References updated with findings of literature review through September 2013.  Outdated web references deleted. 

Medical Policy Panel, November 2014

Medical Policy Group, November 2014 (4): No policy change. Updates to Key Points and References

Medical Policy Group, January 2015 (6): Ad hoc review with update to Key Words to include Cutting Edge MLS M6 Robotic laser, no change to policy statement.

Medical Policy Panel, February 2016

Medical Policy Group, February 2016 (6):  Updates to Description, Key Points, Practice Guidelines and Position Statements, and References; no change to policy statement.

Medical Policy Panel, February 2017

Medical Policy Group, March 2017 (6): Updates to Description, Key Points, Practice Guidelines, Coding and References. No change to policy intent.

Medical Policy Panel, July 2018

Medical Policy Group, July 2018 (6): Updates to Key Points, Practice Guidelines and References.

Medical Policy Group, June 2019: July 2019 quarterly coding update.  Added new CPT code 0552T to Current Coding.

Medical Policy Panel, July 2019

Medical Policy Group, July 2019 (7): Updates to Description, Key Points, References; No change to policy statement.

Medical Policy Panel, October 2020

Medical Policy Group, November 2020 (6): Updates to Policy statement to include medically necessary statement for treatment of oral mucositis only, Key Points, Practice Guidelines, Governing Bodies, Key Words (FX-635, Super Pulsed Laser Technology) and References. On DRAFT through December 19, 2020.

Medical Policy Panel, June 2021

Medical Policy Group, June 2021: Updates to Description, Key Points, Practice Guidelines and References.

Medical Policy Panel, June 2022

Medical Policy Group, June 2022 (6) Updates to Description, Key Points and References.

Medical Policy Group, November 2022 (6): Updates to Policy statement to include coverage may be subject to legislative mandates: Federal Women's Health and Cancer Rights Act (WHCRA).

Medical Policy Group, December 2022 (6): Added Key Words: WHCRA, Women's Health and Cancer Rights Act.

Medical Policy Panel, June 2023

Medical Policy Group, June 2023 (6): Updates to Key Points, Practice Guidelines, Benefit Application and References.

Medical Policy Group, November 2023: 2024 Annual CPT Coding Update: Added 97037.

Medical Policy Panel, June 2024

Medical Policy Group, June 2024 (6): Updates to Key Points, Practice Guidelines and References. Comprehensive non-covered indications updated within Policy statement. No change to policy intent. Title updated "Low Level Laser Therapy".

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield’s administration of plan contracts.

The plan does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. The plan administers benefits based on the member’s contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

As a general rule, benefits are payable under health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage.

The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage:

1. The technology must have final approval from the appropriate government regulatory bodies;

2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes;

3. The technology must improve the net health outcome;

4. The technology must be as beneficial as any established alternatives;

5. The improvement must be attainable outside the investigational setting.

Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are:

1. In accordance with generally accepted standards of medical practice; and

2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient’s illness, injury or disease; and

3. Not primarily for the convenience of the patient, physician or other health care provider; and

4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.